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Introduction
Stem cells are a quintessential key to proper behavior of 
homeostatic processes. Th   ey are often thought of as the 
solution to a wide range of human conditions, with the 
ability to rescue malfunctioning or non-functioning 
organs and tissues. However, there is increasing evidence 
that stem cells can play a central role in disease. Most 
recently, stem cells have been implicated in cancer after 
not responding to homeostasic controls, such as 
proliferation and diﬀ  erentiation [1]. Th  ere are currently 
two models for the cellular origin of cancer and their 
lines are becoming blurred as research in the area con-
tinues (Figure 1). Th   e hierarchy model identiﬁ  es a limited 
number of tumor cells, called cancer stem cells (CSCs), 
capable of initiating a heterogenous tumor, whereas the 
stochastic model describes a probability that speciﬁ  c 
events in a tumor cell population have the potential to 
transform any tumor cell into a tumor-initiating cell [2,3]. 
Cancer is the second leading cause of death in the US, 
and colorectal cancer is the third most common cancer 
among men and women and accounts for 10% of all new 
cancers [4]. Colorectal cancer has been suggested to 
follow a hierarchy or CSC model, being initiated by a 
CSC [5], although not all CSCs are derived from stem 
cells. It is important to note that the CSC hypothesis is 
still a model for how cancer arises and provides resistance 
to therapy. Th  is model is supported by experimental 
evidence [2,6-8] but will need further experimental 
support, particularly in the context of human cancer. 
Further  more, a report by Quintana and colleagues [9] in 
human melanoma suggests the possibility that not all 
cancers follow a CSC model. With a severely immuno-
compromised mouse, 25% of human tumor cells were 
tumorigenic, suggesting that tumorigenic cells are more 
common in some human cancers than previously thought 
[9,10] and may correspond to what is expected in a 
stochastic model more than in a hierarchy model. 
However, the impact and interpretation of studies such as 
these are still up for discussion [8]. Th   is review will focus 
on the most recent evidence for the existence of CSCs 
and their implication in tumorigenesis, metastases, 
recurrence and therapy resistance using colon cancer as a 
model system.
Obedient versus defi  ant stem cells
Self-control and homeostasis
A myriad of cells contribute to the normal function and 
maintenance of adult tissues. Some cells, such as goblet 
cells that produce mucus in the colon, play functional 
roles in speciﬁ   c tissues. Th   ese altruistic cells are 
terminally diﬀ  erentiated and will die serving the tissue. 
Other rare and undiﬀ  erentiated cells, called stem cells, 
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cells while maintaining an adequate supply of themselves 
through the process of self-renewal. Stem cells can divide 
asymmetrically to produce one daughter cell that is more 
committed to a speciﬁ  c cell lineage, a transit-amplifying 
(TA) cell, and one that retains stem-ness. TA cells have a 
limited life span and self-renewal potential while re-
populating the diﬀ  erentiated cells of the tissue.
Th   e colon is organized in this hierarchical fashion and 
its epithelium is renewed every 5 days in humans [11]. In 
this very dynamic process lies a complex collection of 
epithelial cell lineages along with an intricate set of 
molecular mechanisms to maintain order. To preserve 
tissue function, the colon is structurally organized in an 
elegant network of invaginations, termed crypts, which 
aid in the absorption of water and vitamins. Stem cells of 
the colon are located at the base of these crypts and 
produce epithelial cells that are committed to three 
diﬀ  erent cell lineages. Th  ese diﬀ  erentiated cells are the 
absorptive enterocytes, mucus-secreting goblet cells, and 
hormonal enteroendocrine cells that will migrate up the 
crypt wall to form the colon (Figure 2).
Defi  ance and altered management
Since one of the hallmarks of stem cells is their ability to 
self-renew and diﬀ  erentiate, investigators were prompted 
to explore the similarities and diﬀ   erences that exist 
between normal stem cell maintenance of tissues and 
organs and the uncontrolled proliferation of cancer [2]. 
In essence, tumors can be viewed as small aberrant 
organs containing a hierarchy of progenitor cells and 
diﬀ  erentiated cells (Figure 2, for example). Albeit dys-
func  tional when compared to physiologically functioning 
organs, they maintain their own abnormal proliferation 
and survival mechanisms [7]. If tumors are indeed 
aberrant organs, then there is a program by which the 
system is controlled, however loosely it might be. Th  ere-
fore, in the cellular hierarchy of a tumor, there is a 
diﬀ  erentiation mechanism from tumor stem cell to tumor 
progenitor cell to mature tumor cell which ends in 
apoptosis and turnover [6]. Abnormal cellular behavior 
in this tightly controlled system can occur via genetic 
alterations, such as tumor suppressor loss or gene 
destabilization, which result in incremental neoplastic 
gains and disruption of the homeo  static system [12]. 
Figure 1. Model for cellular origin of cancer. Two models are proposed to explain the cellular heterogeneity in cancer: the stochastic model and 
the hierarchy model. In the stochastic model, every tumor cell can stochastically generate a tumor. In the hierarchy model, only the cancer stem 
cells (CSCs) will generate tumors.
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system, cancer will eventually prevail. If the alterations 
can be restricted and coerced to force cells to terminally 
diﬀ  erentiate and die, the invading neoplastic tissue will 
cease to exist.
To determine what makes a normal stem cell mis-
behave, it must ﬁ  rst be determined what makes them   
behave normally. Wnt signaling is one of the driving 
forces in crypt formation and maintenance of the colon 
[13]. When Wnt proteins bind Frizzled/LRP recep  tors, 
the canonical Wnt pathway ensues. Th  is involves the 
disruption of the destruction complex that sequesters 
beta-catenin in the cytoplasm with axin, adenomatous 
polyposis coli (APC), and glycogen synthase kinase 3 
(GSK3) beta. Th   is complex marks beta-catenin for degra-
da  tion and leads to a decrease in Wnt targeted transcrip-
tion. When the complex is disrupted, beta-catenin can 
enter the nucleus and, in concert with transcription 
factor 4 (TCF4), eﬀ  ect transcription of Wnt targets [14]. 
Th   e dysregulation of the Wnt pathway and its role in self-
renewal as well as diﬀ  erentiation have been shown to be 
required for the development of cancer [13]. Deviance in 
any of these factors will tip the balance toward cancer. 
Furthermore, recent in vivo studies in rodents have indi-
cated that colonic crypts are derived from Lgr5+ (leucine-
rich repeat-containing G protein-coupled receptor 
5-positive) crypt base columnar cells. Lineage-tracing 
assays using Lgr5-lacZ mice indicated that the rare crypt 
base columnar cells represent the stem cells of the colon 
[15]. Th  e  Lgr5 gene is a Wnt target and is repressed upon 
inhibition of the pathway [15]. Th  erefore, if aberrantly 
active, the Wnt pathway could result in an expanded 
progenitor population and colon cancer (Figure 1).
One of the most commonly mutated genes in human 
colorectal cancer is Apc, which has been implicated in 
both the sporadic and inherited forms of this cancer [16]. 
As discussed above, this is one of the players involved in 
the destruction of beta-catenin. Upon disruption of this 
protein interaction, beta-catenin is free to roam into the 
nucleus, where it upsets gene transcription via inter-
actions with transcription factors and subsequently 
disrupts homeostasis. Th  is concept was nicely demon-
strated with Lgr5+ colon stem cells when Lgr5-EGFP 
mice with ﬂ  oxed Apc were treated with tamoxifen. Th  e 
resulting deletion of the Apc gene in the stem cell 
compartment supported the idea that stem cell-speciﬁ  c 
Figure 2. Model for colon cancer initiated by stem cells. Colon stem cells are located at the base of the crypt in normal colon and will 
diff  erentiate while moving up the crypt in about 5 days. Adenoma will develop upon deregulation of stem cell homeostasis. Upon further 
neoplastic injuries, stem cells will transform into cancerous stem cells (CSCs) with some limited ability to diff  erentiate.
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eventually cancer [17]. Since some of these transformed 
cells had retained their Lgr5 expression, Lgr5+ tumor 
cells could also be considered true CSCs and the Lgr5 
epitope as a possible CSC marker (Figure 2).
Parallel to the studies investigating Lgr5 and its role as 
a stem cell marker of the intestine was the investigation 
of Bmi1. Bmi1 is a transcriptional receptor in the 
polycomb group (PcG) gene family and is involved in 
stem cell maintenance, proliferation, diﬀ  erentiation  to 
more committed cells, malignant transformation, and 
biologic aggressiveness of human carcinomas [18,19]. It 
is a member of the PcG proteins and, more speciﬁ  cally, 
the polycomb-repressing complex 1 (PRC1), indicating a 
role in maintaining chromatin silencing [20]. As 
expected, any factor involved in gene silencing has the 
capacity to exponentially misbehave. If the genes aﬀ  ected 
are involved in maintaining control, their silencing could 
perturb the structured environment of a tissue. Bmi1 
transcriptionally regulates the INK4a locus encoding 
p16INK4a and p19ARF tumor suppressors [21]. By suppres-
sing a tumor suppressor, a double-negative results in a 
positive for cancer growth as well as for the expansion of 
cells with stem cell properties. Th  erefore, Bmi1 became 
an interesting endeavor for the cancer stem cell biologist. 
As with Lgr5, a lacZ reporter assay identiﬁ  ed Bmi1 as the 
source for all diﬀ  erentiated cells of the mouse intestine. 
In addition, its ablation led to crypt loss and adenoma 
formation upon stable beta-catenin expression in these 
cells [22]. Th  e relation of Bmi1 to cancer was further 
enhanced by expression proﬁ   les, which showed that 
increased Bmi1 expression correlates with poor clinical 
survival in patients with colon cancer [23].
Bmi1 also gives a good example of how epigenetics can 
inﬂ  uence the initiation or propagation of cancer or both. 
Epigenetic modiﬁ  cations can result in altered signaling 
and function, thus contributing to the formation or 
progression of cancer or both [24]. Being a PcG protein, 
Bmi1 coordinates the regulation of histone modiﬁ  cation 
and methylation, adding a layer of epigenetic modiﬁ  -
cation to its already existing regulatory role. As seen in 
breast cancer, Bmi1 overexpression can block terminal 
diﬀ  erentiation, leading to an expansion of cells capable of 
self-renewing [19]. Normally, Bmi1 is lowly expressed in 
diﬀ  erentiated cells and highly expressed in stem cells. 
Th  e increased expression of PcG proteins in metastatic 
breast and prostate cancer occurs in a pool of cancer cells 
with stem cell-like properties, indicating that this 
alteration may occur in the CSC population [25].
Although the studies on Lgr5 and Bmi1 suggest that 
the transformation of stem cells from obedient to deviant 
cells may lead to tumorigenesis, complete molecular 
mechanisms have yet to be resolved. Understanding the 
steps by which stem cell homeostasis is lost and cancer is 
initiated would pave the way for possible cancer 
treatments. Th  e Hedgehog-Gli (HH-Gli) signaling path-
way is proposed as a mechanism through which normal 
stem cell maintenance can be dysregulated, leading to 
colon cancer [26]. In an active HH pathway, Patched is 
blocked, releasing Smoothened to activate Gli. Although 
colon cancers and their stem cells of all stages have active 
HH-Gli signaling, an increase in HH-Gli signaling is seen 
in metastases. Th  is may indicate that while APC/beta-
catenin signaling disruption may be the ﬁ  rst of many hits 
toward colon cancer, HH-Gli may be an added push 
toward deviance [27].
In addition to these pathways, other signaling mecha-
nisms involved in normal stem cell function and 
homeostasis may contribute to the misbehavior evident 
in cancer and its stem cells. Th   ese include the phospha-
tase and tensin homolog (PTEN) and Notch pathways 
[28]. PTEN is a tumor suppressor whereas the Notch 
pathway regulates cell fate decisions [29,30]. PTEN not 
only has been implicated in the signaling of CSCs 
themselves but also has been found in stromal cells of the 
surrounding tumor microenvironment. Th  e  genetic 
inactivation of Pten in stromal ﬁ  broblasts was shown to 
accelerate the initiation, progression, and malignant 
transformation of mammary epithelial tumors in mice, a 
phenotype that was correlated with a speciﬁ  c  PTEN 
signature in patients with breast cancer [31].
Identifying the culprit in human cancer
Unfortunately, identifying CSCs in human cancers has 
remained challenging. CD133, a cell surface marker for 
many normal stem cells, has been thought of as a CSC 
marker in human cancers, and particularly in human 
colon cancer, with some controversy about whether it 
marks the true stem cell population. Using the AC133 
antibody to identify CD133 expression, Ricci-Vitiani and 
colleagues [32] and O’Brien and colleagues [33] both 
showed in 2007 that it is the CD133+ population of 
human colon cancer cells which initiates the tumor 
whereas the CD133− population does not. It seems that 
such a strong correlation would evoke some sort of 
function of CD133 to the cancer-initiating cells. However, 
upon siRNA (short interfering RNA) knockdown, there 
was no impact on proliferation, migration, colony 
formation, or invasion, indicating that while CD133 may 
serve as a prognostic marker of colon cancer and its stem 
cells, it is not a feasible target to eradicate the trouble-
some cells [34]. Importantly, the CD133+ popu  lation of 
tumor cells was found to rely on HH-Gli signaling for 
survival and self-renewal as well as expansion driven by 
increased signaling [27]. Th   erefore, even though CD133 
expression itself does not seem to aﬀ   ect the tumor’s 
properties, it may be able to identify the cells with 
aberrant signaling. Adding to the controversy, the 
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recognizes a glycosylated epitope on the human CD133 
antigen. Furthermore, AC133 is not present on all colon 
cancers and is lost upon diﬀ  erentiation whereas CD133 is 
not [35-37].
Th  e epithelial cell adhesion molecule (EpCAM) is 
another claimed CSC marker that has been implicated in 
stem cell signaling via the Wnt pathway [38]. While 
EpCAM presence is abundant in the membrane of 
normal epithelial tissues, it is prone to cleavage in cancer 
tissue, making it diﬃ   cult to use as a target [39]. CD44 is 
also described as a molecule whose splicing variants were 
shown to be diﬀ   erentially expressed between normal 
stem cells and CSCs [40]. In combi  nation with CD133, 
CD44 and CD166 may provide a better way to identify 
the CSC population. However, this makes therapeutic 
targeting a challenge because of the heterogenous expres-
sion of these markers. Colorectal carcinomas assayed for 
expression of these markers found that CD133 held the 
strongest single-marker adverse correlation with patient 
survival. While CD166 and CD44 alone may have little or 
no correlation with survival, their combined analysis with 
CD133 may allow the separation of low-, intermediate-, 
and high-risk colorectal cancers [41].
Control or destroy?
So how do we control the CSCs? To date, colon cancer 
treatments have often resulted in recurrence and meta-
stases. One reason may be that CSCs are more resistant 
to chemotherapy treatments than their more diﬀ  eren-
tiated progeny are, allowing recurrence and metastases. 
Th  erefore, therapies that target either the terminal 
diﬀ  erentiation or destruction of CSCs must be developed 
[28,42,43]. Th  ere have been great eﬀ  orts to treat acute 
promyelocytic leukemia with all-trans retinoic acid 
(ATRA), which acts to diﬀ  erentiate leukemic pro  myelo-
cytes to normal, terminally diﬀ  erentiated  neutrophils 
[44]. It is thought that such a diﬀ  erentiation therapy may 
be beneﬁ  cial in the emerging population of solid cancers 
that arise from malfunc  tioning CSCs. Th  e  diﬀ  erentiation 
theory would cause CSCs to lose their dangerous edge: 
the ability to self-renew [7]. Another approach would be 
to destroy CSCs directly by harnessing the pathways used 
for CSC mainte  nance and survival [45,46].
What do we know?
A recent study of colon cancer examined FOLFOX 
(folinic acid, 5-ﬂ   uorouracil plus oxaliplatin), a widely 
used treatment for colon cancer [47]. In that study, initial 
treatment of colon cancer cells enriched the population 
for CD133+, CD44+, and/or CD166+ cells with increased 
levels of epidermal growth factor receptor-positive 
(EGFR+). Upon subsequent treatment of the surviving 
cells (the CSCs) with curcumin or curcumin plus 
FOLFOX, a reduction in CSCs was seen. Although the 
mechanism is not fully understood, it was shown to 
increase methylation of the EGFR promoter. Th  is  hyper-
methylation, via changes in the level of DNA methyl-
transferase 1, decreases the expression of EGFR, stabiliz-
ing the chromatin and preventing the binding of trans-
cription factors [47]. While this may be a desired eﬀ  ect, 
care must be taken to investigate possible detri  mental 
eﬀ  ects of this type of treatment. Hyper  methy  lation is also 
known to inactivate the transcription factor p16INK4a [47]. 
As discussed previously, increased Bmi1 expression leads 
to inactivation of p16INK4a. Th   erefore, a therapy that may 
promote hypermethylation and gene silencing may cause 
additional imbalances in the already mischievous CSCs.
Recent drug screenings revealed salinomycin as a 
speciﬁ  c inhibitor of CSCs. Th   is study focused on breast 
cancer and used CD44high/CD24low as the molecular 
proﬁ  le of CSCs. Th  ey found that the number of these 
cells decreased with salinomycin treatment as compared 
with a current treatment of paclitaxel. Surprisingly, 
paclitaxel actually increased the number of CSCs. In 
addition, there was a decrease in tumor sphere formation 
as well as decreased metastases over paclitaxel [48]. 
Although this study used breast cancer as a model, colon 
cancer has been shown to be resistant to paclitaxel. 
Modiﬁ  cations that include the use of a mitogen-activated 
protein kinase (MAPK) inhibitor in combination with 
paclitaxel to enhance apoptosis of colon cancer cells have 
been suggested [49]. In light of the results in breast 
cancer, it may be beneﬁ  cial to investigate the selection of 
colon CSCs by treatment with paclitaxel. Such a 
treatment may give a survival advantage that results in a 
more invasive and aggressive cancer. Th  is is especially 
true given that salinomycin has been shown to induce 
apoptosis as well as overcome apoptotic resistance in 
breast cancer cells [50]. Th  ere is a strong connection 
between colon and breast cancer because they are both 
epithelial cancers that resemble the tissue of origin, even 
at metastatic sites.
Drug screenings such as those mentioned above do not 
take into consideration or deﬁ   ne the mechanisms by 
which the drug has aﬀ  ected the CSC population or the 
tumor as a whole. Several other studies have used what is 
known about stem cell and CSC signaling, discussed 
above, to target CSCs. Th   e HH pathway is active in both 
bulk and stem cell populations of a tumor and therefore it 
may represent a mechanism that can be targeted for 
therapy. One study showed that cyclopamine, an HH 
inhibitor, could increase apoptosis and decrease 
prolifera  tion [51]. In addition, the manipulation of the 
Notch pathway via drug intervention may successfully 
target CSCs. Gamma-secretase inhibitors have been 
shown to reduce cancer growth, inhibit CSC self-renewal, 
and increase diﬀ  erentiation to goblet cells [52,53]. Similar 
Chandler and Lagasse Stem Cell Research & Therapy 2010, 1:13 
http://stemcellres.com/content/1/2/13
Page 5 of 9results were found with small-molecule and RNA knock-
down studies showing that the inhibition of Notch leads 
to increased apoptotsis, decreased self-renewal, and 
increased secretory cell lineage diﬀ  erentiation of CSCs in 
colon cancer [54]. In yet another study focusing on the 
Notch pathway, inhibition of Delta-like ligand 4 (DLL4) 
inhibited the expression of Notch targets and reduced 
tumor-initiating cell frequency [55]. Th  ese  targeted 
therapies may enhance the eﬃ   cacy  of  chemo  therapeutic 
drugs when used in sequence or combination [46]. However, 
one must realize that these are mecha  nisms shared by 
normal intestinal stem cells and may lead to toxicity.
While there are treatments that seem to reduce the 
number of CSCs, two problems remain. Just reducing the 
population of misbehaving cells does not solve the 
problem. As soon as the treatment ceases, these cells can 
again ﬂ  ourish. Unfortunately, thus far, there has been no 
demonstration that targeting CSCs will improve the 
outcome of patients with cancer.
Peer pressure: the mastermind
If stem cells are indeed the culprit behind colon cancer 
and alterations in their behavior are the driving force, 
what causes the alterations? Th   e answer may be genomic 
instability (GI), which could explain why colon cancer 
remains such a diﬃ     cult disease to treat despite the 
breadth of knowledge obtained over recent years. GI 
occurring in stem cells may be one of the initiating peer 
pressure events that drive normal stem cells to go awry 
and become CSCs [56-58]. If it is not an initiating event, 
GI may be the result of other alterations, thus steering 
the stem cell population into cancer. Chromosomal 
aberrations and DNA repair mutations aﬀ  ecting migra-
tion and proliferation in these cells lead to metastases 
and cancers that are more aggressive [59]. In addition to 
carcinogenesis and disease progression, GI may be 
responsible for resistance to current therapies making 
colon cancer such a devastating disease [60]. As men-
tioned previously, current therapies may eﬀ  ectively treat 
the bulk tumor but, in eﬀ  ect, could select for the more 
tumorigenic CSCs. If this is the cell population that 
harbors GI, these cells are more likely to evade the toxic 
eﬀ   ects of cancer drugs by adaptations that only their 
instability has allowed. In essence, natural selection 
selects not only the ﬁ  ttest organisms but also the ﬁ  ttest 
cells [5,36]. After the selective therapy has occurred, the 
population of the ﬁ  ttest cells, which includes those with 
enhanced abilities to migrate and proliferate, expands. 
Even with a change in treatment regimen, GI continues 
to perpetuate the peer pressure to become adaptively 
deviant, resulting in a cancer without restraint.
Two types of GI are present in colon cancer: micro-
satellite instability (MSI) and chromosomal instability 
(CIN). MSI refers to genetic or epigenetic alterations or 
both in DNA mismatch repair mechanisms, including 
MSH2 and MLH1, which can lead to loose control of 
DNA metabolism and cell cycle control and result in 
carcinogenesis [56,57]. Th  is results in a nucleotide 
mutation rate that is two to three orders of magnitude 
greater than that of normal cells [56]. MSI in tumors may 
determine site-related diﬀ   erences when comparing 
proximal and distal colon tumors; therefore, MSI-bearing 
tumors are unique and may be indicative of a class of 
tumors more prone to genetic alterations and adaptations 
[61]. Surprisingly, MSI tumors are associated with a 
better prognosis and are less prone to metastasis than 
their microsatellite-stable (MSS) counterparts [62]. Th  e 
mechanism behind this phenomenon in MSI involves a 
mutation in transforming growth factor-beta receptor 2 
and the resulting inability to undergo epithelial-mesen-
chymal-transition (EMT) as seen with MSS tumors [63]. 
EMT is often associated with the ability of cancers to 
metastasize and therefore leads to a poorer prognosis 
[64]. Such results indicate that GI may not always support 
cancer progression and the use of MSI status for 
prognosis or therapy response or both has the potential 
to improve patient care [58,65]. In addition, the 
information obtained from MSI tumors may unveil ways 
to harness MSS tumors.
While colon cancers with MSI make up only a small 
portion of cases, most of the remaining colon cancers 
exhibit CIN involving an increased tendency for gain or 
loss of chromosomes in part or whole [66]. While 
seemingly minor mutations resulting from MSI have 
been linked to colon cancer, CIN has been linked to the 
previously mentioned Apc mutations commonly seen in 
colon cancer. Prior to the beta-catenin dysregulation that 
results in increased self-renewal, altered APC-mediated 
microtubule regulation may be the ﬁ  rst point of deviance. 
Th   e mitotic inﬁ  delity at this point places CIN earlier in 
carcinogenesis progression that may determine the 
future of a particular colon cancer and has been 
correlated with poor prognosis [67,68]. As a consequence 
of APC deletion, the calcium gradient present in the 
crypts of the colon is perturbed [69]. Normally, Ca+2 
concentrations increase as cells migrate up the crypt. Th  is  is 
paralleled by an increased expression of the calcium-sensing 
receptors (CaSRs) and consequential E-cadherin expression. 
Th  is normal process drives terminal diﬀ  erentiation  and 
apoptosis at the crypt mucosal surface. In cases in which 
APC is lost, an expansion of TA cells below the Ca+2 gradient 
change leads to a pool of proliferating cells that cannot 
express CaSR, thus perpetuating or even accelerating the 
development of disease [70,71]. While it seems as though 
colon cancer will prevail, targeting its GI could be an 
Achilles heel for treatment.
Although GI can be considered the driving force for 
cancer, more importantly, it is the sustained force that 
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[68]. If CSCs can be targeted by approaches that are more 
speciﬁ  c, the fact that GI is also present in these CSCs will 
make them moving targets [60]. As a consequence, both 
the speciﬁ  c targeting of CSCs and the inhibition of GI 
appear to be necessary for a successful approach to 
eradicating cancer in patients.
Conclusions
In colon cancer, like many other cancers, it seems that 
Mother Nature used two of its best creations, stem cells 
and GI, to produce tumor cells with survival skills 
unmatched by any other cells. Pathways such as Wnt, 
Notch, and HH may be potential therapeutic targets to 
force control of CSCs, but owing to GI, these approaches 
may subsequently ﬁ  nd resistance. Th  erefore, treatments 
that are speciﬁ  c to both CSCs and GI may be the only 
solution to this diﬃ   cult problem (Figure 3). Only when 
all CSCs are eradicated via either destruction or terminal 
diﬀ  eren  tiation will cancer be truly cured. However, much 
still needs to be understood about normal stem cell 
versus CSC function and maintenance before eﬀ  ective 
treat  ments can be generated for such deﬁ  ant  cellular 
mechanisms.
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